Literature DB >> 8119179

A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx.

S Fujitani1, T Yada.   

Abstract

It has recently been shown that N-[(trans-4-isopropylcyclohexyl)-carbonyl]D-phenylalanine (A-4166), a new nonsulfonylurea oral hypoglycemic agent, reduces blood glucose levels in nondiabetic and diabetic animals in a quicker and shorter lasting manner than sulfonylureas, and that the hypoglycemic effect of A-4166 is due to the stimulation of insulin release. However, the mechanism by which A-4166 stimulates insulin release is still unknown. In the present study, we investigated the effect of A-4166 on the cytosolic free Ca2+ concentration ([Ca2+]i) in pancreatic beta-cells from normal rats by dual wavelength fura-2 microfluorometry. In the presence of 2.8 mM glucose, A-4166 produced a rapid increase in [Ca2+]i in a concentration-dependent manner over the range of 3-30 microM. The increase in [Ca2+]i was transient, oscillatory, or sustained. A-4166 did not evoke any decrease in [Ca2+]i, whereas a high concentration of glucose (16.7 mM), a metabolized secretagogue, produced an initial decrease and a subsequent increase in [Ca2+]i. In the presence of 16.7 mM glucose, low concentrations (0.03-1 microM) of A-4166 produced an increase in [Ca2+]i in some of the beta-cells tested. The [Ca2+]i response to A-4166 was completely and reversibly inhibited under Ca(2+)-free conditions as well as by nitrendipine, a blocker of the L-type Ca2+ channel. Nitrendipine also inhibited insulin release from perfused rat pancreases stimulated by A-4166. Diazoxide, an opener of the ATP-sensitive K+ channel, blocked the [Ca2+]i response to A-4166. Sulfonylureas such as tolbutamide and glibenclamide increased [Ca2+]i in a manner similar to A-4166. These results indicate that at basal glucose concentrations, A-4166 increases [Ca2+]i in rat pancreatic beta-cells by stimulating Ca2+ influx through L-type Ca2+ channels, and that this effect is markedly augmented at elevated glucose concentrations. It appears that the increase in [Ca2+]i is related to the stimulation of insulin release by A-4166. Inhibition of ATP-sensitive potassium channels, but not stimulation of beta-cell metabolism, may be involved in the increase in [Ca2+]i by A-4166.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119179     DOI: 10.1210/endo.134.3.8119179

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

Authors:  Wei Zhang; Yi-Jing He; Chun-Ting Han; Zhao-Qian Liu; Qing Li; Lan Fan; Zhi-Rong Tan; Wei-Xia Zhang; Bang-Ning Yu; Dan Wang; Dong-Li Hu; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

Review 3.  Nateglinide.

Authors:  C J Dunn; D Faulds
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

4.  Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.

Authors:  Julia Kirchheiner; Ingolf Meineke; Göran Müller; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.

Authors:  A Mori; P Lee; T Yamashita; Y Nishimaki; H Oda; K Saeki; Y Miki; H Mizutani; K Ishioka; T Honjo; T Arai; T Sako
Journal:  Vet Res Commun       Date:  2009-09-02       Impact factor: 2.459

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.